Ethics Washing: The Misappropriation of Ubuntu in the Ethics of Heritable Human Genome Editing (HHGE)
By Anye Nyamnjoh,
EthicsLab
| 11. 15. 2024
In their argument for equal access to heritable human genome editing (HHGE) as a healthcare service for future generations, Shozi and Thaldar invoke Ubuntu, an African philosophy centered on communal harmony, as a moral foundation. However, their engagement with ubuntu reveals a deeper issue: ethics washing. This practice involves using superficial ethical language to legitimize an agenda — in this case, a liberal one focused on expanding HHGE policy—while concealing a lack of substantive engagement with the invoked principles.
This critique is particularly relevant given Thaldar and colleagues’ recent defence of South Africa’s amended research ethics guidelines, which now appear to permit this controversial form of human genome editing. By positioning ubuntu as a moral justification for HHGE, Shozi and Thaldar’s work aligns with this policy shift, lending it an ethical veneer rooted in African values. However, Ubuntu is invoked here to support predetermined liberal goals, such as distributive equality in access to HHGE, without substantively demonstrating how its principles justify these outcomes. As Nyamnjoh and Ewuoso have argued, their claim that participants in a South African public...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...